More News

13 Jan 2020 Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates
13 Jan 2020 Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
13 Jan 2020 Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
13 Jan 2020 Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®
13 Jan 2020 Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
13 Jan 2020 MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab (news with additional features)
12 Jan 2020 Serimmune and Atreca, Inc. Establish Research Collaboration Agreement in Oncology
12 Jan 2020 Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases
12 Jan 2020 Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
12 Jan 2020 Bayer and Azitra partner to harness the human skin microbiome as a source for new natural skin care products for sensitive and eczema-prone skin
11 Jan 2020 Lilly Announces Agreement to Acquire Dermira
10 Jan 2020 Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery
09 Jan 2020 Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies
09 Jan 2020 CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics
09 Jan 2020 eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types
09 Jan 2020 Kaleido Biosciences Announces Collaboration with Janssen to Explore the Potential for Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions by Promoting Healthy Function of the Gut Microbiome
09 Jan 2020 Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides
09 Jan 2020 Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
09 Jan 2020 Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
09 Jan 2020 Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
09 Jan 2020 Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome
09 Jan 2020 Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
09 Jan 2020 Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
09 Jan 2020 WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
09 Jan 2020 SAB Biotherapeutics Announces Research Collaboration With CSL Behring

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up